Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo
The ESRRA gene encodes a transcription factor and regulates several genes, such as WNT11 and OPN , involved in tumorigenesis. It is upregulated in several cancers, including OSCC. We have previously shown that the tumor suppressor miR-125a targets ESRRA and its downregulation causes upregulation of...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2015-12, Vol.5 (1), p.17621, Article 17621 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The
ESRRA
gene encodes a transcription factor and regulates several genes, such as
WNT11
and
OPN
, involved in tumorigenesis. It is upregulated in several cancers, including OSCC. We have previously shown that the tumor suppressor miR-125a targets
ESRRA
and its downregulation causes upregulation of ESRRA in OSCC. Upregulation of ESRRA in the absence of downregulation of miR-125a in a subset of OSCC samples suggests the involvement of an alternative mechanism. Using TaqMan
®
copy number assay, here we report for the first time that the genomic amplification of
ESRRA
causes its upregulation in a subset of OSCC samples. Ectopic overexpression of ESRRA led to accelerated cell proliferation, anchorage-independent cell growth and invasion and inhibited apoptosis. Whereas, knockdown of ESRRA expression by siRNA led to reduced cell proliferation, anchorage-independent cell growth and invasion and accelerated apoptosis. Furthermore, the delivery of a synthetic biostable
ESRRA
siRNA to OSCC cells resulted in regression of xenografts in nude mice. Thus, the genomic amplification of
ESRRA
is another novel mechanism for its upregulation in OSCC. Based on our
in vitro
and
in vivo
experiments, we suggest that targeting
ESRRA
by siRNA could be a novel therapeutic strategy for OSCC and other cancers. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep17621 |